Loading stock data…
GILD
$131.65+0.81 (+0.62%)
Market ClosedLast close May 1
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gilead Sciences, Inc. in the Healthcare sector is trading at $131.65. The stock is currently 16% below its 52-week high of $157.29, remaining 4.8% above its 200-day moving average. Technical signals show neutral RSI of 32 and bearish MACD signal, explaining why GILD maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 32) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$131.65
Potential Upside
20.2%
Whystock Fair Value$158.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus28 analysts
Buy
Mean target$158.36+20.3%
Range$123.00 – $180.00
Fundamentals
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$164.96B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.60
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Strong income play. Yield provides a meaningful total return floor.
247.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
27.80%
Volume
Today's trading volume
5.52M
Recent News
Gilead’s HIV Priority Review And Arcellx Deal Refocus Long‑Term Story
FDA accepts Gilead Sciences' New Drug Application for a once-daily single-tablet HIV regimen combining bictegravir and lenacapavir, granting priority review with an expected decision by late August 2026. Phase 3 data for the regimen have shown encouraging efficacy and tolerability in people living with HIV. Gilead completes its acquisition of Arcellx, adding an investigational CAR T cell therapy for multiple myeloma to its pipeline. Gilead Sciences, NasdaqGS:GILD, is drawing attention as it...
Assessing Gilead Sciences (GILD) Valuation As Long Term Returns Contrast With Recent Share Performance
What recent performance suggests about Gilead Sciences (GILD) With no single headline event in focus, attention on Gilead Sciences (GILD) has centered on its recent share performance and business profile, prompting investors to reassess how the biopharma stock fits into their portfolios. See our latest analysis for Gilead Sciences. Gilead Sciences’ share price has eased in recent months, with a 30 day share price return of 6.17% and a 90 day share price return of 7.26%. However, the 1 year...
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Kymera Therapeutics tops Q1 revenue estimates on strong Gilead collaboration, as pipeline advances and KT-200 milestone deal boost outlook.
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could shape the outlook.
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
Gilead Sciences (GILD) closed at $130.84 in the latest trading session, marking a +1.55% move from the prior day.